Barricaid vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Barricaid (by Intrinsic Therapeutics) is an FDA-approved bone-anchored annular closure device implanted in 12,000+ patients; CMS raised its ASC reimbursement 46% in 2025; first awake-surgery and endoscopic implantations achieved in 2025.
About
Barricaid is the commercial brand name for the Barricaid Annular Closure Device (ACD), a medical device developed and marketed by Intrinsic Therapeutics, a clinical-stage medical device company. The Barricaid ACD received FDA premarket approval on February 8, 2019. It is designed to treat lumbar disc herniation by sealing tears in the annulus fibrosus — the tough outer layer of spinal discs — following discectomy (the surgical removal of herniated disc material). By closing the annular defect, Barricaid aims to contain remaining disc material, reduce the likelihood of reherniation, and alleviate nerve compression and back pain.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.